SELLAS Life Sciences Group, Inc.
SLS Nasdaq· Pharmaceutical Preparations
Last close · Oct 23, 2026
$11.54
KIRA · Stoqly’s AI analyst, in plain words
- SELLAS Life Sciences Group, Inc. lost $26.9M in fiscal 2025.
Market cap
$2.2B
P/E
—
Revenue
—
Net income
−$26.9M
Free cash flow
—
Operating margin
—
SELLAS Life Sciences Group, Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−$26.9M
No. It lost money last year.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What SELLAS Life Sciences Group, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 19, 2026
- Legal name
- SELLAS Life Sciences Group, Inc.
- CIK
- 0001390478
SELLAS Life Sciences Group, Inc. · SLS
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $7.6M | $1.0M | $0.0M | — | — |
| Revenue growth | 300.0% | −86.8% | −100.0% | — | — |
| Net interest income | $0.0M | $0.3M | $0.5M | — | — |
| Gross margin | 97.4% | 90.0% | — | — | — |
| Operating margin | −332.8% | −4,195.0% | — | — | — |
| Net income | −$20.7M | −$41.3M | −$37.3M | −$30.9M | −$26.9M |
| Net margin | −272.4% | −4,130.1% | — | — | — |
| Diluted EPS | −$1.34 | −$2.13 | −$1.34 | −$0.50 | −$0.25 |
| Cash | |||||
| Cash from operations | −$26.0M | −$23.8M | −$31.4M | −$35.4M | −$28.4M |
| Share count change | 94.1% | 25.3% | 43.2% | 120.3% | 78.2% |
| Debt and strength | |||||
| Cash and short-term investments | $21.4M | $17.1M | $2.5M | $13.9M | $71.8M |
| Shareholders' equity | $20.3M | $4.9M | −$8.0M | $9.5M | $70.9M |
| Current ratio | 4.6x | 1.1x | 0.2x | 1.7x | 10.7x |
| Returns and quality | |||||
| Return on equity | −85.7% | −327.8% | — | −4,147.9% | −66.9% |
| Return on tangible equity | −112.3% | −1,406.2% | — | −409.0% | −39.0% |
| Piotroski F-score | 2 | 1 | 1 | — | — |
| Altman Z'' | −15.6 | −40.4 | −166.5 | −49.2 | 1.8 |
Insiders bought, 12 months
$0.1M
1 insider
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
SELLAS Life Sciences Group, Inc. · SLS
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $11.54 a share, the company is worth $2.2B.
Source: SEC EDGAR XBRL filings (CIK 0001390478). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.